I would hold thru this dip...it will bounce back. I think most were worried about the comment CEO made about not going forward with Phase 3 vk5211 without a Partner. But given the fact that the P2 results were excellent I doubt they will have trouble finding a Partner by late summer when they meet with FDA . Also the the CEO mentioned vk2809 was going well but enrollment was hard because of the specific requirements they want in their patients.
The only thing you need to know while holding for another 6 months is they will have a Partner for vk5211 soon and Vk2809 had better P1 report than MDGL lipid drug did and if it has good results in P2 I expect a valuation similar to MDGL....which would put VKTX at 30.00 around late summer or early Fall. Until then is a slow grind up to 12.00 range JMHO
News 
Market Data 
Discover 
